Kanamycin
- Generic Name
- Kanamycin
- Drug Type
- Small Molecule
- Chemical Formula
- C18H36N4O11
- CAS Number
- 59-01-8
- Unique Ingredient Identifier
- EQK9Q303C5
- Background
Kanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections. Kanamycin is isolated from the bacterium Streptomyces kanamyceticus and its most commonly used form is kanamycin sulfate.
- Indication
For treatment of infections where one or more of the following are the known or suspected pathogens: E. coli, Proteus species (both indole-positive and indole-negative), E. aerogenes, K. pneumoniae, S. marcescens, and Acinetobacter species.
- Associated Conditions
- Bacterial Infection caused by Acinetobacter species, Bacterial Infection caused by E. coli, Bacterial Infection caused by Enterobacter aerogenes, Bacterial Infection caused by Klebsiella Pneumoniae, Bacterial Infection caused by Proteus species, Bacterial Infection caused by Serratia marcescens
An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis
- Conditions
- TuberculosisMultidrug Resistant TuberculosisExtensively-drug Resistant Tuberculosis
- Interventions
- First Posted Date
- 2015-05-27
- Last Posted Date
- 2021-09-29
- Lead Sponsor
- University of Cape Town
- Target Recruit Count
- 154
- Registration Number
- NCT02454205
- Locations
- 🇿🇦
Brooklyn Chest Hospital, Cape Town, Western Cape, South Africa
The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB
- Conditions
- MDR-TB
- Interventions
- Drug: Regimen A locally-used WHO-approved MDR-TB regimen (2011 guideline)
- First Posted Date
- 2015-04-06
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- IUATLD, Inc
- Target Recruit Count
- 588
- Registration Number
- NCT02409290
- Locations
- 🇪🇹
Armauer Hanssen Research Institute, Addis Ababa, Ethiopia
🇪🇹St. Peter's Tuberculosis Specializes Hospital, Addis Ababa, Ethiopia
🇬🇪JSC National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia
Measurement of Anti-TB Drugs in Lung Tissue From Patients Having Surgery to Treat Tuberculosis
- Conditions
- Tuberculosis
- Interventions
- First Posted Date
- 2009-01-01
- Last Posted Date
- 2019-12-09
- Target Recruit Count
- 19
- Registration Number
- NCT00816426
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
🇰🇷Pusan National Unversity Hospital (PNUH), Busan, Korea, Republic of
🇰🇷National Medical Center, Seoul, Korea, Republic of
Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Conditions
- HIV Infections
- Interventions
- Drug: darunavir/ritonavir dosage #1Drug: TAF w/cobicistatDrug: elvitegravir/cobicistatDrug: darunavir/cobicistatDrug: atazanavir/cobicistatDrug: lopinavir/ritonavir dosage #1Drug: atazanavir/ritonavir/tenofovir dosage #1Drug: lopinavir/ritonavir dosage #2Drug: indinavir/ritonavir dosage #1Drug: atazanavir/ritonavir dosage #1Drug: tipranavir/ritonavirDrug: darunavir/ritonavir dosage #4Drug: indinavir/ritonavir dosage #2Drug: darunavir/ritonavir dosage #2Drug: lopinavir/ritonavir dosage #3Drug: lopinavir/ritonavir dosage #4Drug: tenofovir/atazanavir/ritonavir dosage #2Drug: atazanavir/ritonavir dosage #2Drug: darunavir/ritonavir dosage #3Drug: levoflaxacinDrug: ethionamide/prothionamideDrug: terizidone/cycloserineDrug: para-aminosalicylic acid (PAS)
- First Posted Date
- 2002-08-01
- Last Posted Date
- 2022-07-22
- Target Recruit Count
- 1578
- Registration Number
- NCT00042289
- Locations
- 🇺🇸
Usc La Nichd Crs, Los Angeles, California, United States
🇿🇦Wits RHI Shandukani Research Centre CRS, Johannesburg, Gauteng, South Africa
🇺🇸Boston Medical Center Ped. HIV Program NICHD CRS, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.